Mizuho Maintains Buy on Sabra Health Care REIT, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Vikram Malhotra has reaffirmed a Buy rating on Sabra Health Care REIT (NASDAQ:SBRA) and increased the price target from $15 to $17, indicating a positive outlook on the company's stock.
January 03, 2024 | 3:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Vikram Malhotra maintains a Buy rating on Sabra Health Care REIT and raises the price target from $15 to $17, suggesting a bullish stance on the stock.
The increase in price target by a reputable analyst typically signals a positive outlook on the stock, which can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100